NASDAQ:MRTX - Mirati Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$37.46 -0.95 (-2.47 %)
(As of 11/13/2018 12:56 PM ET)
Previous Close$38.41
Today's Range$37.46 - $39.24
52-Week Range$12.85 - $65.35
Volume8,189 shs
Average Volume1.04 million shs
Market Capitalization$1.29 billion
P/E Ratio-13.46
Dividend YieldN/A
Beta1.83
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRTX
Previous Symbol
CUSIPN/A
Phone858-332-3410

Debt

Debt-to-Equity RatioN/A
Current Ratio11.22
Quick Ratio11.22

Price-To-Earnings

Trailing P/E Ratio-13.46
Forward P/E Ratio-11.74
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.31 per share
Price / Book7.05

Profitability

EPS (Most Recent Fiscal Year)($2.78)
Net Income$-70,420,000.00
Net MarginsN/A
Return on Equity-46.80%
Return on Assets-42.71%

Miscellaneous

Employees51
Outstanding Shares32,520,000
Market Cap$1.29 billion
OptionableOptionable

Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics Inc (NASDAQ:MRTX) released its earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.85) EPS for the quarter, beating the Zacks' consensus estimate of ($0.87) by $0.02. View Mirati Therapeutics' Earnings History.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Mirati Therapeutics.

What price target have analysts set for MRTX?

9 brokerages have issued 12-month price objectives for Mirati Therapeutics' stock. Their predictions range from $9.00 to $65.00. On average, they expect Mirati Therapeutics' share price to reach $50.8571 in the next twelve months. This suggests a possible upside of 35.8% from the stock's current price. View Analyst Price Targets for Mirati Therapeutics.

What is the consensus analysts' recommendation for Mirati Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.

What are Wall Street analysts saying about Mirati Therapeutics stock?

Here are some recent quotes from research analysts about Mirati Therapeutics stock:
  • 1. HC Wainwright analysts commented, "We derive our $65 price target from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for sitravatinib and mocetinostat. We use the net present value of our revenue forecast through 2027, apply a 50% probability of success (POS) for sitravatinib in combination with checkpoint inhibitors, a 45% POS for sitravatinib monotherapy, 15% POS for mocetinostat, our YE2018 fully diluted net cash estimate of $4.79/share, and we value the early stage pipeline at $5.38/ share to arrive at our price target. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 4x." (11/12/2018)
  • 2. Cann analysts commented, "Loss per share was $0.85, compared to our estimated loss of $0.84. Operating expenses were 13% higher than our estimate, but were offset by higher interest income and higher number of shares outstanding, both due to the equity offering. Our revenue outlook for 2018-2023 is unchanged. We are increasing our estimate of operating expenses 6.3% in 2018 and expenses are unchanged for 2019-2023. We are increasing our estimated 2018 loss per share by 1.4% and, due to higher shares outstanding, we are decreasing our estimated loss per share in 2019-2022, by 8.1-8.5% per year. We are decreasing 2023 EPS by 2.2%." (11/6/2018)
  • 3. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (10/4/2018)

Has Mirati Therapeutics been receiving favorable news coverage?

News coverage about MRTX stock has trended somewhat positive on Tuesday, InfoTrie reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mirati Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future.

Who are some of Mirati Therapeutics' key competitors?

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the folowing people:
  • Dr. Rodney W. Lappe, Exec. Chairman (Age 63)
  • Dr. Charles M. Baum, Pres, CEO & Director (Age 60)
  • Dr. James Christensen, Sr. VP & Chief Scientific Officer (Age 50)
  • Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 56)
  • Mr. Jamie A. Donadio, Sr. VP & CFO (Age 43)

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (6.59%), BlackRock Inc. (4.88%), Janus Henderson Group PLC (3.17%), Jennison Associates LLC (3.09%), Credit Suisse AG (1.38%) and Dimensional Fund Advisors LP (0.93%). Company insiders that own Mirati Therapeutics stock include Boxer Capital, Llc, Charles M Baum, Jamie A Donadio, Jamie Christensen, Ltd Braslyn, Tuesday Thirteen Inc and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

Which institutional investors are selling Mirati Therapeutics stock?

MRTX stock was sold by a variety of institutional investors in the last quarter, including EAM Investors LLC, Dimensional Fund Advisors LP, Chicago Equity Partners LLC, PNC Financial Services Group Inc., EAM Global Investors LLC and Bank of New York Mellon Corp. Company insiders that have sold Mirati Therapeutics company stock in the last year include Charles M Baum, Jamie A Donadio and Jamie Christensen. View Insider Buying and Selling for Mirati Therapeutics.

Which institutional investors are buying Mirati Therapeutics stock?

MRTX stock was bought by a variety of institutional investors in the last quarter, including Credit Suisse AG, Jennison Associates LLC, Janus Henderson Group PLC, Wells Fargo & Company MN, Pictet Asset Management Ltd., FMR LLC, BlackRock Inc. and Candriam Luxembourg S.C.A.. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, Ltd Braslyn and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $37.46.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $1.29 billion. The biotechnology company earns $-70,420,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Mirati Therapeutics employs 51 workers across the globe.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is http://www.mirati.com.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]


MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  206 (Vote Underperform)
Total Votes:  504
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Featured Article: Liquidity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel